MARIO ALFREDO RODRIGUEZ-LEON

Dr. MARIO ALFREDO RODRIGUEZ-LEON

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2024 in Clinical and Experimental Dental Research
Verified
Journal Article
Open access
Victor Hugo Urrutia-BacaVictor Hugo Urrutia-Baca
Victor Hugo Urrutia-Baca
BPBrenda Astrid Paz-Michel
Brenda Astrid Paz-Michel
ACAlma Nidia Calderon‐Porras
Alma Nidia Calderon‐Porras
JVJany Ariadne Jiménez‐Del Valle
Jany Ariadne Jiménez‐Del Valle
WAWendy Jazmin Alvarez‐Fernández
Wendy Jazmin Alvarez‐Fernández
Myriam Angelica De La Garza-RamosMyriam Angelica De La Garza-Ramos
Myriam Angelica De La Garza-Ramos
Objectives: Helicobacter pylori gastric infection strongly correlates with gastric diseases such as chronic gastritis, functional dyspepsia, and complications such as peptic ulcers and gastric cancer. In developing countries, systemic therapies are not usually successful due to elevated antibiotic resistance. Additionally, oral H. pylori infection and periodontal disease correlate with gastric treatment failures. This study aimed to explore the effect of an integral therapy, comprising oral hygiene and concomitant systemic treatment, to increase the eradication of gastric infection and recurrences.Materials and Methods: A prospective, randomized, four‐arm, parallel‐group, open‐label clinical trial was conducted to investigate the efficacy of integral therapy to eradicate gastric H. pylori infection and avoid recurrences in double‐positive (real‐time PCR oral and gastric infection) patients. Oral hygiene involved mouthwash with neutral electrolyzed water (NEW), with or without periodontal treatment. One hundred patients were equally distributed into four groups: NS, NS‐PT, NEW, and NEW‐PT. All patients had concomitant systemic therapy and additionally, the following oral treatments: mouthwash with normal saline (NS), periodontal treatment and mouthwash with normal saline (NS‐PT), mouthwash with NEW (NEW), and periodontal treatment and mouthwash with NEW (NEW‐PT). Gastric and oral infection and symptoms were evaluated one and four months after treatments.Results: Integral therapy with NEW‐PT increased gastric eradication rates compared with NS or NS‐PT (84%−96% vs. 20%−56%; p < 0.001). Even more, a protective effect of 81.2% (RR = 0.1877; 95% CI: 0.0658−0.5355; p = 0.0018) against recurrences and 76.6% (RR = 0.2439; 95% CI: 0.1380−0.4310; p < 0.001) against treatment failure (eradication of infection and associated symptoms) was observed in patients from the NEW and NEW‐PT groups.Conclusions: Implementation of oral hygiene and systemic treatment can increase the eradication of gastric infection, associated symptoms, and recurrences. NEW is recommended as an antiseptic mouthwash due to its efficacy and short‐ and long‐term safety.

3 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaúl Romero-Cabello
Raúl Romero-Cabello
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
Valeria Magali Rocha RochaValeria Magali Rocha Rocha
Valeria Magali Rocha Rocha
RFRaul Romero Feregrino
Raul Romero Feregrino
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
Background: Influenza has continued to be an important public health challenge, and the WHO recommends that countries consider vaccination for persons at high risk. Mexico has such a program, and we sought to determine its current situation. Material and Methods: This study has an ecological, longitudinal, and retrospective design based on secondary information on the acquisition and application of vaccines against influenza from official data from 2006 to 2022. Results: We found annual variability in the numbers of purchases and application of doses, with coverage of less than 90% of the total population every year; in addition, 17 million vaccines were not used in this period. Discussion: This study shows the situation of the program at the national level. Two institutions acquired fewer the vaccines, while one purchased more for its target population, but the necessary vaccinations were not acquired. On average, 1.7 million of the vaccines purchased annually were not used, but in some years, more vaccines were applied than were purchased in all of the institutions. We also observed that, between institutions, the vaccine coverage was very different, from 21% to 180%. On average, 6.2 million people were not vaccinated annually, between 16% and 22% of the target population, demonstrating low coverage. When we compared the coverage data that we calculated to the data published by the institutions, a great difference was observed. Conclusions: We found inconsistencies in the data, indicating their unreliability and potential disorganization within the program, as the target populations of each institution were not clear. In addition, the application data may have had reporting errors. Adequate coverage was not achieved, and the coverage was different from that reported in the official sources. We propose the implementation of different systems for control, evaluation, and access to the information of the program.

22 February 2013 in BMC Public Health
Verified
Journal Article
Open access
PDF file
VMVíctor Manuel Mendoza-Núñez
Víctor Manuel Mendoza-Núñez
CMCecilia Mecalco-Herrera
Cecilia Mecalco-Herrera
COCosme Ortega-Ávila
Cosme Ortega-Ávila
LMLaura Mecalco-Herrera
Laura Mecalco-Herrera
JSJuan Luis Soto-Espinosa
Juan Luis Soto-Espinosa
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
Several studies have reported the following as determining factors for the adoption of healthy lifestyles among undergraduate students: gender, socioeconomic level, prior lifestyles, environment, parental lifestyles and health status, career choice, and healthy support networks. However, these factors are influenced by students’ knowledge about healthy lifestyles.

2 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaul Romero-Cabello
Raul Romero-Cabello
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
RFRaul Romero Feregrino
Raul Romero Feregrino
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
JAJulieta Isabel Aguilar-Feregrino
Julieta Isabel Aguilar-Feregrino
Background: In recent years in Mexico, a decreased Bacillus Calmette and Guérin (BCG) coverage has been observed concomitantly with new cases of tuberculosis. Material and Methods: This study is a descriptive and analytical evaluation regarding both BCG vaccine acquisition and coverage as reported by official sources over a 16-year period (2006–2021). Results: We found that vaccine acquisition, dose application and coverage are highly variable each year. Coverage is 90% or higher, except for the 2017–2020 period. Discussion: According to our calculations, between 3,917,616 and 4,961,868 individuals did not receive the BCG vaccine. Coverage was lower than 90% during the last 4 years, whereas this value decreased to 21% in 2020. Except for the last 5 years, the amount of acquired doses surpassed the demand thus causing a considerable vaccine wastage. Conclusions: BCG vaccine coverage is low and many individuals remain unprotected. The access to this vaccine is difficult and the number of newly reported cases of tuberculosis have increased during the last years. Thus, it is necessary to establish vaccination campaigns aimed protect the population and also to deploy a nominal system to control coverage, acquisitions, and target population.

RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaúl Romero-Cabello
Raúl Romero-Cabello
RFRaul Romero Feregrino
Raul Romero Feregrino
PVPaulina Vilchis-Mora
Paulina Vilchis-Mora
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
Introduction: In 2008, Mexico initiated its national HPV vaccination program targeting adolescent girls. This study aims to evaluate the current status of the program, analyzing trends in vaccine acquisition, administration, and coverage over a 16-year period. Materials and Methods: A retrospective longitudinal study was conducted using secondary data from 2008 to 2023. Official records from three major public health institutions—IMSS, ISSSTE, and SSA—were reviewed to assess HPV vaccine procurement and administration. Results: Significant fluctuations were identified in the number of doses acquired, administered, and the corresponding coverage rates. A marked decline was observed between 2019 and 2021, followed by a sharp increase in 2022 and 2023. Over the entire period, an estimated 6.8 million doses were not administered to the intended target population. Furthermore, 2.6 million doses were administered in excess of the number officially acquired, indicating possible discrepancies in data reporting or vaccine inventory management. Discussion: The findings revealed substantial inconsistencies in vaccine procurement, administration, and coverage across institutions. While IMSS and ISSSTE consistently reported coverage below the theoretical target, SSA occasionally exceeded expectations, potentially compensating for deficits elsewhere. Nevertheless, national coverage remained inadequate in several years, with notable disparities between institutions. These gaps highlight systemic weaknesses in program coordination, planning, and data transparency, contributing to millions of unvaccinated individuals. Conclusions: This study offers a comprehensive analysis of Mexico’s HPV vaccination program, uncovering critical irregularities in its implementation. Challenges include inaccurate target population estimation, inconsistencies between vaccine acquisition and administration, and limited data reliability. Despite some progress in recent years, particularly in the post-pandemic years, the program requires urgent restructuring. This includes implementing a national catch-up strategy, expanding vaccine eligibility, and strengthening surveillance systems to ensure equitable and effective coverage toward the elimination of cervical cancer.

1 January 2021 in Revista Mexicana de Patología Clínica y Medicina de Laboratorio
Verified
Journal Article
Closed access
PDF file
RCRaúl Romero Cabello
Raúl Romero Cabello
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON